These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 27981445

  • 1. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
    Liu F, Meng Z, Shao G, Wang J, Wang Z, Yang J, Yip CS, He D.
    Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
    [Abstract] [Full Text] [Related]

  • 2. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX, Chen J, Bai T, Zhu SL, Yang TB, Qi LN, Zou L, Li ZH, Ye JZ, Li LQ.
    BMC Cancer; 2017 Sep 12; 17(1):645. PubMed ID: 28899349
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W, Wang YJ, Zhao Y, Qi XS, Yin ZX, He CY, Li RJ, Wu KC, Xia JL, Fan DM, Han GH.
    J Dig Dis; 2013 Apr 12; 14(4):181-90. PubMed ID: 23324079
    [Abstract] [Full Text] [Related]

  • 4. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y, Chen B, Liu N, Li N, Dao H, Chen W, Yang J.
    Int J Clin Pharmacol Ther; 2017 Jun 12; 55(6):498-508. PubMed ID: 28157070
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G, Kus T, Emin Kalender M, Kervancioglu S, Sevinc A, Kul S, Camci C.
    J BUON; 2017 Jun 12; 22(1):150-156. PubMed ID: 28365948
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    Zhao Y, Li H, Bai W, Liu J, Lv W, Sahu S, Guan S, Qin X, Wang W, Ren W, Mu W, Guo W, Gu S, Ma Y, Yin Z, Guo W, Wang W, Wang Y, Duran R, Fan D, Zhang Z, Han G.
    Int J Cancer; 2016 Aug 15; 139(4):928-37. PubMed ID: 27038145
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
    Yao X, Yan D, Zeng H, Liu D, Li H.
    J Surg Oncol; 2016 May 15; 113(6):672-7. PubMed ID: 26989044
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J.
    J Hepatol; 2016 May 15; 64(5):1090-1098. PubMed ID: 26809111
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
    Fu S, Chen S, Liang C, Liu Z, Zhu Y, Li Y, Lu L.
    Oncotarget; 2017 Jun 06; 8(23):37855-37865. PubMed ID: 27911268
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial.
    Han G, Yang J, Shao G, Teng G, Wang M, Yang J, Liu Z, Feng G, Yang R, Lu L, Chao Y, Wang J.
    Future Oncol; 2013 Mar 06; 9(3):403-10. PubMed ID: 23469975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.